Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by stormAcute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.176In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care.
Source: Nature Clinical Practice Oncology - Category: Cancer & Oncology Authors: Source Type: research